Today, HDT Bio Corp., a clinical-stage private firm specializing in advanced RNA products for treating and preventing infectious diseases and cancer, revealed its participation in the World Vaccine Congress West Coast 2023 in Santa Clara, California, running from November 27 to 30, 2023.
READ: “Veterinarians Issue Warning as Cases Surge for Unidentified Canine Illness”
HDT Bio’s AMPLIFY vaccine platform integrates repRNA coding for an antigen target and LION™ formulation technology, offering a versatile solution for various pathologies, from infectious diseases to cancer. Compared to traditional RNA vaccines, this platform provides enhanced safety and potency, simplified manufacturing, and improved temperature stability, allowing for increased efficacy and potential multivalency.
HDT Bio
Dr. Steven Reed, CEO of HDT Bio, will moderate a panel titled “SupeRNAtural: Realizing the potential of RNA therapeutics for ID & Cancer” on Wednesday, November 29, at 10:15 a.m. PT in Hall B. Panelists include Dr. Zelanna Goldberg, Chief Medical Officer of Replicate Bioscience, Inc., Dr. Robert Shoemaker, Co-Chief of Chemopreventive Agent Development at the National Cancer Institute, and Dr. Joshua DiNapoli, Global Project Head mRNA Platform of Sanofi. The discussion will cover the diverse range of RNA molecules inhibiting infectious diseases and cancer, addressing common challenges within the field.
HDT Bio
Dr. Steven Reed will also present “AMPLIFY Vaccine Platform: repRNA + LION™” as part of the Cancer and Immunotherapy segment on Wednesday, November 29, at 1:05 p.m. PT, focusing on the enhanced manufacturing flexibility, improved storage stability, and increased cellular immune responses of HDT Bio’s AMPLIFY platform.
Furthermore, Dr. Darrick Carter, Co-Founder and Senior Advisor of HDT Bio, will present “JO – opening tumor junctions to treat cancer” during the Immune Profiling session on Wednesday, November 29, at 3:30 p.m. PT.
Dr. Steven Reed, CEO of HDT Bio, stated, “The World Vaccine Congress West Coast 2023 serves as an impactful platform integrating advancements in cancer and infectious disease research, bringing together innovative minds in vaccines and immunology. At HDT Bio, we’re committed to pioneering RNA technologies for preventive healthcare, and we eagerly anticipate sharing insights, exchanging ideas, and collaborating with the brilliant minds gathered at this conference. We’ll highlight the advances of our AMPLIFY vaccine platform and our ACCESS junction opener technology designed to improve tumor penetrance.”
About HDT Bio:
HDT Bio, a Seattle-based clinical-stage biopharmaceutical development company, focuses on harnessing host-directed immune responses through nucleic acid formulation. The company collaborates globally on infectious disease and oncology vaccines and therapeutics. HDT Bio’s vaccine platforms stabilize and deliver RNA to the immune system, with repRNA/LION™ being the first self-amplifying RNA vaccine platform to receive regulatory authorization.
-
-
-
-
